Guestimating Molecular Subtyping of Breast Cancer by Ki67 in the Era of Artificial Intelligence.
[AIMS] This study aimed to compare the performance of immunohistochemistry (IHC)-based luminal subtyping of breast cancer against gene expression panels at our institute and to evaluate a CE-certified
APA
Connolly CE, Sgier BP, et al. (2026). Guestimating Molecular Subtyping of Breast Cancer by Ki67 in the Era of Artificial Intelligence.. International journal of breast cancer, 2026, 9640277. https://doi.org/10.1155/ijbc/9640277
MLA
Connolly CE, et al.. "Guestimating Molecular Subtyping of Breast Cancer by Ki67 in the Era of Artificial Intelligence.." International journal of breast cancer, vol. 2026, 2026, pp. 9640277.
PMID
41488588
Abstract
[AIMS] This study aimed to compare the performance of immunohistochemistry (IHC)-based luminal subtyping of breast cancer against gene expression panels at our institute and to evaluate a CE-certified artificial intelligence (AI) Ki67 image analysis program for improving subtyping accuracy.
[METHODS AND RESULTS] We retrospectively analysed IHC-based luminal subtyping in breast cancer biopsies diagnosed at our institute from 2019 to 2022 ( = 1736), and identified = 104 (Oncotype DX) and = 64 (EndoPredict) cases with gene expression tests requested by clinicians. Of the eligible ER-positive HER2-negative cases, 11.9% ( = 168) underwent multigene testing. After excluding incomplete data ( = 22), gene tests revealed 48 patients (32.9%) would benefit from chemotherapy, 86 (58.9%) could avoid it and 12 (8.2%) had inconclusive results. A moderate correlation was observed between Ki67 and EndoPredict EPClin scores ( = 0.47-0.58) and a weak correlation between Ki67 and Oncotype DX recurrence scores ( = 0.31-0.38). Ki67 scores were significantly higher in luminal B compared with luminal A tumours (difference of 9.1-15.2, < 0.01). No significant difference was found between mean Ki67 scores reported by pathologists and AI (pathologists' mean Ki67 17.36 vs. AI mean Ki67 18.36, = 146, = 0.456) and the accuracy of luminal subtyping was similar between pathologists and AI (accuracy pathologists 66.4% vs. AI 62.7%, = 0.538).
[CONCLUSIONS] Our data provides a snapshot of the real-world allocation of multigene testing in early breast cancer, and supports other studies in highlighting the discrepancy between IHC-based and gene-based luminal subtyping. Ki67 evaluation remained consistent over time, and the use of AI for Ki67 scoring did not enhance the accuracy of IHC-based luminal subtyping.
[METHODS AND RESULTS] We retrospectively analysed IHC-based luminal subtyping in breast cancer biopsies diagnosed at our institute from 2019 to 2022 ( = 1736), and identified = 104 (Oncotype DX) and = 64 (EndoPredict) cases with gene expression tests requested by clinicians. Of the eligible ER-positive HER2-negative cases, 11.9% ( = 168) underwent multigene testing. After excluding incomplete data ( = 22), gene tests revealed 48 patients (32.9%) would benefit from chemotherapy, 86 (58.9%) could avoid it and 12 (8.2%) had inconclusive results. A moderate correlation was observed between Ki67 and EndoPredict EPClin scores ( = 0.47-0.58) and a weak correlation between Ki67 and Oncotype DX recurrence scores ( = 0.31-0.38). Ki67 scores were significantly higher in luminal B compared with luminal A tumours (difference of 9.1-15.2, < 0.01). No significant difference was found between mean Ki67 scores reported by pathologists and AI (pathologists' mean Ki67 17.36 vs. AI mean Ki67 18.36, = 146, = 0.456) and the accuracy of luminal subtyping was similar between pathologists and AI (accuracy pathologists 66.4% vs. AI 62.7%, = 0.538).
[CONCLUSIONS] Our data provides a snapshot of the real-world allocation of multigene testing in early breast cancer, and supports other studies in highlighting the discrepancy between IHC-based and gene-based luminal subtyping. Ki67 evaluation remained consistent over time, and the use of AI for Ki67 scoring did not enhance the accuracy of IHC-based luminal subtyping.